NEI Podcast – Details, episodes & analysis

In recognition of Stress Awareness Week, the NEI Podcast revisits a vital conversation with Dr. Joan Striebel about the syndrome of catatonia—a condition that can emerge from profound psychological or physiological stress. Dr. Andy Cutler and Dr. Striebel discuss its dynamic presentation, the importance of treating underlying causes, and why clinicians should maintain a high index of suspicion when evaluating complex or unexplained psychiatric symptoms. This re-release highlights key insights to help clinicians recognize and manage catatonia more effectively in practice. 

Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast 

Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp  

Stay updated with email alerts and join our conversations on social. Follow us on: 

• YouTube: https://nei.global/youtube 

• Instagram: https://nei.global/instagram 

• LinkedIn: https://nei.global/linkedin 

• Facebook: https://nei.global/facebook 

• X: https://nei.global/twitter 

In this episode, Dr. Andy Cutler talks with Dr. Ryan Sultán about the evolving landscape of ADHD—why diagnoses and prescriptions have risen across age groups, what recent prescribing data reveal, and how these trends align with real-world clinical experience. They explore how ADHD medications affect not just symptoms but broader outcomes like school, work, and safety, while also addressing concerns about overdiagnosis, misuse, and disparities in access to care.  

Dr. Ryan Sultan is a board-certified adult and child psychiatrist specializing in attention-deficit/hyperactivity disorder (ADHD) and assistant professor at Columbia University Irving Medical Center and the New York State Psychiatric Institute. He is the Medical Director of NYC-based Integrative Psychiatry, where he assesses and treats patients using a combination of psychological, social, environmental, and pharmacological modalities. Integrative Psychiatry also provides ADHD treatment in Miami. As an ADHD psychiatrist, he conducts extensive ADHD research with a focus on using big data to improve ADHD treatment in real world settings, advocating for non-pharmacological interventions such as cognitive behavioral therapy (CBT) for ADHD, coaching, and digital tools as a foundational treatment that precedes or supplements medication. He approaches ADHD treatment with a nuanced understanding of the current misuse and overdiagnosis crisis, and addresses this issue through careful assessment and monitoring.  

Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York. 

Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast 

Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp  

Stay updated with email alerts and join our conversations on social. Follow us on: 

• YouTube: https://nei.global/youtube 

• Instagram: https://nei.global/instagram 

• LinkedIn: https://nei.global/linkedin 

• Facebook: https://nei.global/facebook 

• X: https://nei.global/twitter 

In this CME podcast episode, Dr. Andrew Cutler interviews Dr. Phillip Coffin, Director of the Center on Substance Use and Health in San Francisco, CA, about the management of stimulant use disorders. They explore the challenges of treatment and highlight the importance of harm reduction strategies to enhance patients' quality of life.  

NEI Members can earn CME/CE by participating in this activity here: https://nei.global/e257-cme 

Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast 

Interested in Psychopharmacology?  Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp  

Stay updated with email alerts and join our conversations on social. Follow us on: 

• YouTube: https://nei.global/youtube 

• Instagram: https://nei.global/instagram 

• LinkedIn: https://nei.global/linkedin 

• Facebook: https://nei.global/facebook 

• X: https://nei.global/twitter 

In this episode, Dr. Napoleon Higgins answers your important questions from his presentation, To the Moon and Back: Pediatric ADHD.

In this episode, Dr. Andy Cutler addresses your unanswered questions from his presentation, New Kids on the Block: Novel Receptor Science in the Treatment of Major Depressive Disorder.

In this episode, Dr. Jeffrey Strawn answers your most pressing questions from his presentation, Blue Genes: Using Pharmacogenetics to Guide Prescribing.

In this episode, Dr. Adelaide Robb addresses your unanswered questions from her presentation: Assessment and Treatment of Pediatric Impulsive Aggression: A Transdiagnostic Issue.

What are the early diagnostic stages of Alzheimer's disease? What sort of brain changes can occur up to 20 years prior to symptoms of Alzheimer's disease?

In this episode, Dr. Danielle Goldfarb addresses these questions and much more! She shares the most current research on dementia and geriatrics relevant to clinical practice. She also shares resources for early diagnosis of dementia and treating mental health in geriatrics.

Dr. Danielle Goldfarb is an Assistant Professor of Neurology and Psychiatry at the University of Arizona and a dual board-certified neurologist and psychiatrist at the Banner Sun Health Research Institute and Cleo Roberts Memory Center in Sun City, AZ.  Dr. Goldfarb cares for patients and families with Alzheimer's disease and related dementias (ADRD). She leads several Alzheimer's clinical trials and is involved in research efforts to explore the neuropathologic substrates of early neuropsychiatric symptoms in ADRD, to improve the safety and efficiency of  the collection of cerebrospinal fluid biomarkers in older adults, and to expand access to ADRD care and research by underserved communities.

What made you both want to write the book "Management of Complex Treatment-Resistant Psychotic Disorders? What are some of the most challenging components to treat, when it comes to complex psychosis and how are these addressed in the book?

In this episode, Dr. Andrew Cutler interviews Dr. Michael Cummings on how to manage complex treatment-resistant psychotic disorder.

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology.

Episodes to be released under this theme include:

Part 1: Management of Complex Treatment-Resistant Psychotic Disorders with Dr. Michael Cummings

Part 2: The Clozapine Handbook with Dr. Jonathan Meyer

Part 3: Don't Guess! Measure: The Clinical Use of Antipsychotic Plasma Levels with Dr. Jonathan Meyer

Subscribe to the NEI Podcast, so that you don't miss another episode!

What are some of the major differences between intravenous or IV ketamine and intranasal esketamine? How are you building on these research findings and what associated avenues have been explored?

In this episode, we interview the poster winner from last year's NEI Congress, Dr. Balwinder Singh on his research comparing intravenous ketamine and intranasal esketamine. The study, conducted at Mayo Clinic rendered interesting findings that may be important for clinicians.

Dr. Balwinder Singh is a Consultant and Assistant professor in the Department of Psychiatry at Mayo Clinic in Rochester, Minnesota. He is a psychiatrist specializing in mood disorders, and his research is focused on novel treatments for treatment-resistant depression and identifying biomarkers for ketamine response.  He is also involved in the ketamine and esketamine clinic practice at the Mayo Clinic Depression Center.  

This is one of the first studies to highlight a faster response to intravenous ketamine as compared to intranasal esketamine in an observational study.

Title: Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study
Byline: Balwinder Singh; Simon Kung; Vanessa Pazdernik; Kathryn M. Schak; Jennifer Geske; Phillip J. Schulte; Mark A. Frye; Jennifer L. Vande Voort
Citation: J Clin Psychiatry 2023;84(2):22m14548
DOI: https://doi.org/10.4088/JCP.22m14548
URL: Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study | Psychiatrist.com